A transgenic mouse model for high content, cell cycle phenotype screening in live primary cells

Area of Science:

• * Biotechnology and Drug Discovery
• * Cell Biology and Genetics

Background:

• * High-content screening (HCS) using cell-based assays is crucial for drug discovery and understanding disease mechanisms.
• * Current methods often require complex cell manipulation like transfection or immunocytochemistry, adding time and cost.

Purpose of the Study:

• * To develop a more efficient method for phenotype analysis in drug discovery.
• * To create a transgenic mouse model for unambiguous, real-time monitoring of cellular processes.
• * To facilitate the discovery of novel chemotherapeutic compounds.

Main Methods:

• * Utilized a transgenic mouse model engineered to express a fluorescence mitosis biosensor in primary cells.
• * Employed time-lapse live fluorescence microscopy to capture cellular events.
• * Analyzed phenotype profiles related to cell cycle disruption and apoptosis at a single time point.

Main Results:

• * The biosensor enabled unambiguous phenotype readouts directly from primary cells, eliminating the need for transfection or immunocytochemistry.
• * Cell cycle disruption and apoptosis were readily detectable using this system.
• * The model successfully demonstrated the potential for generating biosensor-expressing primary cancer cells.

Conclusions:

• * This transgenic mouse model offers a powerful and efficient platform for high-content screening in drug discovery.
• * The system simplifies the analysis of cellular phenotypes, accelerating the identification of potential therapeutic agents.
• * The model holds significant promise for discovering tumor-specific chemotherapeutic compounds by crossing with existing cancer models.